Please use this identifier to cite or link to this item:
|Title:||Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role?|
|Authors:||Yip, G;Ekinci, Elif I;Lee, S T;Jerums, George;Grossmann, Mathis|
|Affiliation:||Department of Medicine, Austin Health, Heidelberg, Victoria, Australiatoria, Australia|
|Citation:||Internal Medicine Journal; 40(4): 300-3|
|Abstract:||Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.|
|Internal ID Number:||20529040|
Antibodies, Antineutrophil Cytoplasmic.biosynthesis.blood.physiology
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.